Lupus anticoagulant and anticardiolipin antibodies in serum of patients treated with risperidone

Journal of Clinical Psychiatry

Volumn 70, Issue 5, 2009, Pages 769-771

  Schwartz, Miguel ^a   Kormilachev, Maria ^b   Kushnir, Mina ^b   Weller, Boaz ^a   Rochas, Marina ^b   Toubi, Elias ^a  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b Flugelman Psychiatrie Hospital   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; CARBAMAZEPINE; CARDIOLIPIN ANTIBODY; CLONAZEPAM; FOLIC ACID; LUPUS ANTICOAGULANT; NIFEDIPINE; OXAZEPAM; PAROXETINE; PHOSPHOLIPID ANTIBODY; RISPERIDONE;

ADULT; ANTIBODY BLOOD LEVEL; BLOOD EXAMINATION; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; FEMALE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTIPSYCHOTIC AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 67049173927     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08l04572     Document Type: Letter

References (10)

1. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294(15):1934-1943 (Pubitemid 41464695)
2. Center for Drug Evaluation and Research. Deaths with antipsychotics in elderly patients with behavioral disturbances. April 11, 2005. US Food and Drug Administration Web site. Drug Information page. Available at: http://www.fda.gov/CDER/drug/advisory/antipsychotics.htm. Accessibility verified Feb 9, 2009
3. Schwartz M, Rochas M, Weller B, et al. High association of anticardiolipin antibodies with psychosis. J Clin Psychiatry 1998;59(1):20-23 (Pubitemid 28243771)
4. Schwartz M, Rochas M, Toubi E, et al. The presence of lupus anticoagulant and anticardiolipin antibodies in patients undergoing long-term neuroleptic treatment. J Psychiatry Neurosci 1999;24(4):351-352
5. Zuckerman E, Toubi E, Shiran A, et al. Anticardiolipin antibodies and acute myocardial infarction in nonsystemic lupus erythematosus patients: a controlled prospective study. Am J Med 1996;101(4):381-386 (Pubitemid 26392855)
6. Brandt JT, Triplett DA, Alving B, et al, on behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Criteria for the diagnosis of lupus anticoagulant: an update. Thromb Haemost 1995;74(4):1185-1190
7. Janssen-Ortho, Inc. Risperdal (risperidone) and cerebrovascular adverse events in placebo-controlled dementia trials. Letter to Health Care Professionals. Oct 11, 2002. Accessed Oct 17, 2007. Available at: http://www.hc-sc.gc.ca/dhp-mps/alt-formats/hpfb-dgpsa/pdf/medeff/ risperdal-hpc-cps-eng.pdf
8. US Food & Drug Administration. 2003 Safety alert: Risperdal (risperidone).Washington, DC: US Dept Health Human Services. April 16, 2003. Available at: http://www.fda.gov/medwatch/SAFETY/2003/safety03.htm#risper. Accessibility verified Feb 9, 2009
9. Percudani M, Barbui C, Fortino I, et al. Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. J Clin Psychopharmacol 2005;25(5):468-470 (Pubitemid 41368370)
10. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self-controlled case series study. BMJ 2008;337:a1227